Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H34N4O5S |
Molecular Weight | 490.616 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O
InChI
InChIKey=WIGIZIANZCJQQY-RUCARUNLSA-N
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
Molecular Formula | C24H34N4O5S |
Molecular Weight | 490.616 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:28 UTC 2023
by
admin
on
Fri Dec 15 15:51:28 UTC 2023
|
Record UNII |
6KY687524K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
LIVERTOX |
459
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-VATC |
QA10BD06
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-VATC |
QA10BB12
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
NCI_THESAURUS |
C97936
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-ATC |
A10BB12
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-ATC |
A10BD06
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-ATC |
A10BD04
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
NDF-RT |
N0000175608
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
||
|
WHO-VATC |
QA10BD04
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1481
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
C29073
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
25789
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | RxNorm | ||
|
GLIMEPIRIDE
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
1292303
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
m5745
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | Merck Index | ||
|
93479-97-1
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
Glimepiride
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
6KY687524K
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
5383
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
100000085456
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
SUB07925MIG
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
5718
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
DB00222
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
759809
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
6820
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
6KY687524K
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
C057619
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
DTXSID5040675
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
EE-37
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY | |||
|
1300
Created by
admin on Fri Dec 15 15:51:28 UTC 2023 , Edited by admin on Fri Dec 15 15:51:28 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> SUBSTRATE |
Clearance of glimepiridein OATP1B1*5 and *15 was significantly reduced compared to the wild-type.
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Clearance of glimepiride CYP2C9*2 and *3 was significantly reduced compared to the wild-type.
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||